Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 177HER2-positive Breast Cancer 16Neoplasms 11Neoplasm Metastasis 10Prostatic Neoplasms 7Ovarian Neoplasms 7Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Inflammatory Breast Neoplasms 5Colonic Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Multiple Myeloma 4Hematologic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Solid Tumor 3Rectal Neoplasms 3Pathologic Complete Response 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3HER2-positive Early Breast Cancer 3Esophageal Neoplasms 3Breast Neoplasms, Male 3Biliary Tract Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Salivary Gland Neoplasms 2Locally Advanced Breast Cancer 2

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 35Peripheral Blood Stem Cell Transplantation 31dinutuximab 29Radiotherapy 29Granulocyte Colony-Stimulating Factor 29sargramostim 283-Iodobenzylguanidine 27Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16Ifosfamide 15naxitamab 14fludarabine phosphate 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroblastoma × pertuzumab × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡